IPHYF fundamentals
An in-depth look to Innate Pharma operating, investing, and financing activities
IPHYF free cash flow for H2 23 is -23.33 M USD. For 2023, IPHYF free cash flow was -36.32 M USD and operating cash flow was -35.94 M USD.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
TTM